VIDEO: Cardiac events can be more likely with androgen deprivation therapy

ByDavid Statman

In this video, Alicia Morgans, MD, discusses a study on the association of intermittent or continuous androgen deprivation therapy with cardiovascular disease and endocrine/metabolic disorders in patients with nonmetastatic prostate cancer.

Morgans, a medical oncologist at Dana-Farber Cancer Institute, co-presented the study at ASCO Genitourinary Cancers Symposium that involved looking for the incidence of major adverse cardiac events in these patients, and compared the rates of these and the development of major endocrine disorders, finding a higher rate of patients with cardiac events.

“When we looked deeper at this cohort of patients, we found that those patients who had a history of risk factors [for] (cardiac events) continued to have a higher risk [for] developing these adverse events,” Morgans said.

Reference:

Morgans A, et al. Association of intermittent or continuous androgen deprivation therapy with cardiovascular disease and endocrine/metabolic disorders in patients with nonmetastatic prostate cancer. Presented at: ASCO Genitourinary Cancers Symposium; Feb. 16-18, 2023; San Francisco.

Published by:

Sources/Disclosures

Collapse

Disclosures: Morgans reports consulting for Advanced Accelerator Applications, Astellas Pharma, AstraZeneca, Bayer, Blue Earth Diagnostics, Exelixis, Janssen, Lantheus Medical Imaging, Merck, Myovant Sciences, Myriad Genetics, Novartis and Sanofi; and receiving research funding from Astellas Scientific and Medical Affairs Inc, AstraZeneca, Bayer, Dendreon, Genentech, Myovant Sciences, Sanofi and Seagen/Astellas.

Take Homes in Prostate Cancer

Read more

VIDEO: Cardiac events can be more likely with androgen deprivation therapy

Reference:

Related Content